Trial: 202007159

A Phase 1/2, Multi-Center, Dose-Escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (And Young Adults Aged up to 21 Years) with FLT3-ITD Mutations



Principal Investigator

Hayashi, Robert

Disease Site

Myeloid and Monocytic Leukemia

Learn more about this study at: